About Tenet Medicines
Tenet Medicines was founded in 2023 and is based in Scotch Plains, United States. Focus is placed on the biotechnology sector, where therapeutics for autoimmune-driven inflammatory diseases are developed. The product pipeline includes TNT119, also known as budoprutug, an anti-CD19 monoclonal antibody designed to deplete B-cells. Indications addressed include systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. Operations center on advancing these treatments through clinical development.
- Headquarter Scotch Plains, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Eliem Therapeutics
(Apr 11, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Tenet Medicines
Detailed funding history for Tenet Medicines
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Tenet Medicines
Tenet Medicines has secured backing from 1 investor. Prominent investors backing the company include Eliem Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
Locked | Locked | Locked |
Investor details for Tenet Medicines
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tenet Medicines
Investment portfolio details for Tenet Medicines
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tenet Medicines
Detailed financials for Tenet Medicines
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tenet Medicines Comparisons
Peer comparison for Tenet Medicines
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tenet Medicines
Detailed competitors of Tenet Medicines
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tenet Medicines
Complete news archive for Tenet Medicines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tenet Medicines
Tenet Medicines was founded in 2023.
Tenet Medicines is headquartered in Scotch Plains, United States. It is registered at Scotch Plains, New Jersey, United States.
Stephen Thomas is the current CEO of Tenet Medicines.
Tenet Medicines was founded in 2023 and is based in Scotch Plains, United States. Focus is placed on the biotechnology sector, where therapeutics for autoimmune-driven inflammatory diseases are developed. The product pipeline includes TNT119, also known as budoprutug, an anti-CD19 monoclonal antibody designed to deplete B-cells. Indications addressed include systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. Operations center on advancing these treatments through clinical development.
Tenet Medicines has 1 investor. Key investors include Eliem Therapeutics.